Literature DB >> 6602860

Clonal analysis of cytotoxic T cell response against human melanoma.

B Mukherji, T J MacAlister.   

Abstract

We investigated the feasibility of generating cytotoxic T cell clones against autologous human melanoma cells using a melanoma cell line (VIP) and a spontaneously transformed autologous fibroblast line (VIP-F:T). Cytotoxic lymphocytes (CL) generated against the VIP melanoma cells in one-way mixed lymphocyte-tumor cell interactions were expanded in interleukin 2 for 2 wk. The expanded CL were cloned in limiting dilution. Two phenotypically homogeneous clones (3:1 and E.5) were obtained bearing OKT3 phenotype. Both clones expressed cytotoxicity selectively only against the sensitizing autologous target VIP. cytotoxicity assays performed with clone E.5 against the VIP target cells in the presence of autologous unfractionated lymphocytes or serum showed no modulation of autoreactivity of clone E.5. These results indicate that analysis of cellular immune response against autologous tumor cells might be feasible using autoreactive clones generated by the currently available in vitro cloning technology.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6602860      PMCID： PMC2187080          DOI： 10.1084/jem.158.1.240

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  9 in total

1.  Studies on cytotoxicity generated in human mixed lymphocyte cultures. I. Time course and target spectrum of several distinct concomitant cytotoxic activities.

Authors:  J K Seeley; S H Golub
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

2.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

3.  Spontaneous in vitro cytotoxicity against autochthonous human melanoma cells.

Authors:  B Mukherji; A Flowers; L Rothman; L Nathanson
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

4.  Variables and specificity of in vitro lymphocyte-mediated cytotoxicity in human melanoma.

Authors:  B Mukherji; D Vassos; A Flowers; S C Binder; L Nathanson
Journal:  Cancer Res       Date:  1975-12       Impact factor: 12.701

5.  Cytotoxic effects of antigen- and mitogen-induced T cells on various targets.

Authors:  M J Bevan; M Cohn
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

6.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Authors:  M T Lotze; E A Grimm; A Mazumder; J L Strausser; S A Rosenberg
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

7.  Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media.

Authors:  J W Mier; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

8.  Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.

Authors:  A Mazumder; E A Grimm; H Z Zhang; S A Rosenberg
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphcoytes.

Authors:  F T Vánky; S A Argov; S A Einhorn; E Klein
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307
  9 in total
  39 in total

Review 1.  Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy.

Authors:  Arvind Chhabra
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Intensity of the vaccine-elicited immune response determines tumor clearance.

Authors:  Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors:  P Hersey; M MacDonald; S Schibeci; C Burns
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.

Authors:  R Somasundaram; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients.

Authors:  S Yamasaki; T Okino; N G Chakraborty; W O Adkisson; A Sampieri; S J Padula; F Mauri; B Mukherji
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

7.  An efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinoma.

Authors:  Glenda Canderan; Paola Gruarin; Daniela Montagna; Raffaella Fontana; Gabriele Campi; Giulio Melloni; Catia Traversari; Paolo Dellabona; Giulia Casorati
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

8.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Authors:  A Knuth; B Danowski; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 9.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

10.  Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2.

Authors:  J R Sporn; M T Ergin; G R Robbins; R G Cable; H Silver; B Mukherji
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.